{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:13:49Z","timestamp":1748405629584,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10096-025-05090-z","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T08:23:41Z","timestamp":1741422221000},"page":"1493-1500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacodynamic target attainment of the synergism of ceftazidime-avibactam in combination with amikacin against OXA-producing extensively drug-resistant or pan drug-resistant (XDR\/PDR) Pseudomonas aeruginosa"],"prefix":"10.1007","volume":"44","author":[{"given":"Yixin","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"4","key":"5090_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","volume":"21","author":"A Ardebili","year":"2023","unstructured":"Ardebili A, Izanloo A, Rastegar M (2023) Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy? Expert Rev Anti Infect Ther 21(4):387\u2013429","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"5090_CR2","doi-asserted-by":"publisher","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","volume":"56","author":"E Del Barrio-Tofino","year":"2020","unstructured":"Del Barrio-Tofino E, Lopez-Causape C, Oliver A (2020) Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired beta-lactamases: 2020 update. Int J Antimicrob Agents 56(6):106196","journal-title":"Int J Antimicrob Agents"},{"key":"5090_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","volume":"21\u201322","author":"A Oliver","year":"2015","unstructured":"Oliver A, Mulet X, Lopez-Causape C, Juan C (2015) The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 21\u201322:41\u201359","journal-title":"Drug Resist Updat"},{"issue":"4","key":"5090_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jmii.2023.01.017","volume":"56","author":"M Zeng","year":"2023","unstructured":"Zeng M, Xia J, Zong Z, Shi Y, Ni Y, Hu F, Chen Y, Zhuo C, Hu B, Lv X, Li J, Liu Z, Zhang J, Yang W, Yang F, Yang Q, Zhou H, Li X, Wang J, Li Y, Ren J, Chen B, Chen D, Wu A, Guan X, Qu J, Wu D, Huang X, Qiu H, Xu Y, Yu Y, Wang M (2023) Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli. J Microbiol Immunol Infect 56(4):653\u2013671","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"5090_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12941-020-00389-5","volume":"19","author":"Z Chegini","year":"2020","unstructured":"Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A (2020) Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Ann Clin Microbiol Antimicrob 19(1):45","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"5090_CR6","doi-asserted-by":"publisher","unstructured":"Horcajada JP, Montero M, Oliver A, Sorli L, Luque S, Gomez-Zorrilla S, Benito N, Grau S (2019) Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev 32(4). https:\/\/doi.org\/10.1128\/CMR.00031-19","DOI":"10.1128\/CMR.00031-19"},{"key":"5090_CR7","unstructured":"Product information. Ceftazidime and avibactam sodium for injection.\u00a0https:\/\/reference.medscape.com\/drug\/avycaz-ceftazidime-avibactam-999985#5"},{"key":"5090_CR8","unstructured":"(2012) Aminoglycosides. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)"},{"issue":"1","key":"5090_CR9","first-page":"1","volume":"9","author":"MM Montera","year":"2021","unstructured":"Montera MM, Ochoa SD, L\u00f3pez-Causap\u00e9 C, Luque S, Sorl\u00ed L, Campillo N, Montesinos IL, Padilla E, Prim N, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP (2021) Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against ceftazidime-avibactam-resistant isolates. Microbiology Spectrum 9(1):1\u20138","journal-title":"Microbiology Spectrum"},{"issue":"2","key":"5090_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC (1995) The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47(2):331\u2013385","journal-title":"Pharmacol Rev"},{"issue":"1","key":"5090_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1089\/sur.2018.141","volume":"20","author":"GE Stein","year":"2019","unstructured":"Stein GE, Smith CL, Scharmen A, Kidd JM, Cooper C, Kuti J, Mitra S, Nicolau DP, Havlichek DH (2019) Pharmacokinetic and pharmacodynamic analysis of ceftazidime\/avibactam in critically Ill patients. Surg Infect (Larchmt) 20(1):55\u201361","journal-title":"Surg Infect (Larchmt)"},{"key":"5090_CR12","doi-asserted-by":"publisher","unstructured":"Valero A, Rodriguez-Gascon A, Isla A, Barrasa H, Del Barrio-Tofino E, Oliver A, Canut A, Solinis MA (2021) Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK\/PD Analysis. Pharmaceutics 13(11). https:\/\/doi.org\/10.3390\/pharmaceutics13111899","DOI":"10.3390\/pharmaceutics13111899"},{"issue":"1","key":"5090_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","volume":"17","author":"H Kato","year":"2017","unstructured":"Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H (2017) Evaluation of Amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R D 17(1):177\u2013187","journal-title":"Drugs R D"},{"key":"5090_CR14","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.3389\/fmicb.2019.02777","volume":"10","author":"X Song","year":"2019","unstructured":"Song X, Wu Y, Cao L, Yao D, Long M (2019) Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible Bacterial Strains? A pharmacokinetic\/pharmacodynamic modeling with Monte Carlo simulation. Front Microbiol 10:2777","journal-title":"Front Microbiol"},{"key":"5090_CR15","doi-asserted-by":"publisher","unstructured":"Nichols WW, Newell P, Critchley IA, Riccobene T, Das S (2018) Avibactam pharmacokinetic\/pharmacodynamic targets. Antimicrob Agents Chemother 62(6). https:\/\/doi.org\/10.1128\/AAC.02446-17","DOI":"10.1128\/AAC.02446-17"},{"key":"5090_CR16","doi-asserted-by":"publisher","unstructured":"Almarzoky Abuhussain SS, Kuti JL, Nicolau DP (2018) antibacterial activity of human simulated epithelial lining fluid concentrations of ceftazidime-avibactam alone or in combination with Amikacin Inhale (BAY41\u20136551) against carbapenem-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother 62(7).\u00a0https:\/\/doi.org\/10.1128\/aac.00113-18","DOI":"10.1128\/aac.00113-18"},{"key":"5090_CR17","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Blanco JS, S\u00e1ez Fern\u00e1ndez EM, Calvo MV, Lanao JM, Mart\u00edn-Su\u00e1rez A (2021) Evaluation of current amikacin dosing recommendations and development of an interactive nomogram: the role of albumin. Pharmaceutics 13(2). https:\/\/doi.org\/10.3390\/pharmaceutics13020264","DOI":"10.3390\/pharmaceutics13020264"},{"key":"5090_CR18","doi-asserted-by":"publisher","unstructured":"Kang Y, Xie L, Yang J, Cui J (2023) Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR\/PDR) Pseudomonas aeruginosa. Front Cell Infect Microbiol 13.\u00a0https:\/\/doi.org\/10.3389\/fcimb.2023.1023948","DOI":"10.3389\/fcimb.2023.1023948"},{"key":"5090_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jgar.2021.07.020","volume":"27","author":"Y Kang","year":"2021","unstructured":"Kang Y, Zhou Q, Cui J (2021) Pharmacokinetic\/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime\/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China. J Glob Antimicrob Resist 27:67\u201371","journal-title":"J Glob Antimicrob Resist"},{"issue":"12","key":"5090_CR20","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","volume":"74","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2022) Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis 74(12):2089\u20132114","journal-title":"Clin Infect Dis"},{"key":"5090_CR21","doi-asserted-by":"publisher","unstructured":"Ismail A, Ali SSM, Altayeb HN, Alla AA, Moglad EH, Elmissbah TE, Elaskary A, Dahlawi H (2021) Detection of TEM, AmpC, SHV, CTX-M, and MCR-1 genes in gram negative isolates of urinary tract infections. Clin Lab 67(12). https:\/\/doi.org\/10.7754\/Clin.Lab.2021.210315","DOI":"10.7754\/Clin.Lab.2021.210315"},{"issue":"1","key":"5090_CR22","first-page":"e13783","volume":"8","author":"M Bokaeian","year":"2015","unstructured":"Bokaeian M, Shahraki Zahedani S, Soltanian Bajgiran M, Ansari Moghaddam A (2015) Frequency of PER, VEB, SHV, TEM and CTX-M genes in resistant strains of Pseudomonas aeruginosa producing extended spectrum \u03b2-Lactamases. Jundishapur J Microbiol 8(1):e13783","journal-title":"Jundishapur J Microbiol"},{"issue":"1","key":"5090_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12941-022-00510-w","volume":"21","author":"MH Haider","year":"2022","unstructured":"Haider MH, McHugh TD, Roulston K, Arruda LB, Sadouki Z, Riaz S (2022) Detection of carbapenemases bla(OXA48)-bla(KPC)-bla(NDM)-bla(VIM) and extended-spectrum-\u03b2-lactamase bla(OXA1)-bla(SHV)-bla(TEM) genes in Gram-negative bacterial isolates from ICU burns patients. Ann Clin Microbiol Antimicrob 21(1):18","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"5090_CR24","doi-asserted-by":"publisher","first-page":"823684","DOI":"10.3389\/fcimb.2022.823684","volume":"12","author":"SS Jean","year":"2022","unstructured":"Jean SS, Harnod D, Hsueh PR (2022) Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol 12:823684","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"5090_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","volume":"45","author":"A Potron","year":"2015","unstructured":"Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. Int J Antimicrob Agents 45(6):568\u2013585","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"5090_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7883\/yoken.JJID.2022.289","volume":"76","author":"Y Kang","year":"2023","unstructured":"Kang Y, Cui J (2023) Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime\/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic\/Pharmacodynamic Analysis. Jpn J Infect Dis 76(1):1\u20136","journal-title":"Jpn J Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05090-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T12:57:42Z","timestamp":1748350662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["5090"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05090-z","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work did not involve ethical issues. The study does not involve patients\u2019 privacy. No ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}